Follow-up Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-L)

Key facts

Sponsor

Beijing Northland Biotech. Co., Ltd.

Intervention

NL003(drug)

Enrollment

542 enrolled

Eligibility

20-85 years · All sexes

Timeline

2025 – 2027

Study locations (5)

• Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality, China
• Chifeng Municipal Hospital, Chifeng, Neimenggu, China
• zhongshan Hospital Affiliated of Dalian University, Dalian, Shenyang, China
• The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
• The First Affiliated Hospital of Xi 'an Jiaotong University, Xi'an, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Buerger disease

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07215923
  A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers
  Antidote Therapeutics, Inc
• RECRUITINGPHASE4NCT05854615
  Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease
  Cell Biopeutics Resources Sdn Bhd

See all trials for Buerger disease →